Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies

Joe Sasadeusz, Andrew Grigg, Peter D. Hughes, Seng Lee Lim, Michaela Lucas, Geoff McColl, Sue Anne McLachlan, Marion G. Peters, Nicholas Shackel, Monica Slavin, Vijaya Sundararajan, Alexander Thompson, Joseph Doyle, James Rickard, Peter De Cruz, Robert G. Gish, Kumar Visvanathan

Research output: Contribution to journalReview ArticleOtherpeer-review

1 Citation (Scopus)


Patients with malignancies require chemotherapy and other immunosuppressive therapies for treatment. Because of this immunosuppression, in patients who have ever been exposed to hepatitis B it is possible for reactivation to occur. This reactivation can be fatal. Reactivation is particularly likely in patients who receive B cell–active agents such as rituximab. The occurrence of reactivation flares may also delay further chemotherapy, which can negatively affect the outcome of the underlying malignancy. Accordingly, it is important to screen patients for markers of hepatitis B and institute antiviral prophylaxis to prevent reactivation.

Original languageEnglish
Pages (from-to)511-519
Number of pages9
JournalClinics in Liver Disease
Issue number3
Publication statusPublished - 1 Aug 2019


  • Cancer
  • Hematological malignancy
  • Hepatitis B
  • Prophylaxis
  • Reactivation
  • Rituximab
  • Solid tumors

Cite this